Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? (Q30778435)

14 October 2017

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? (English)

1 reference

14 October 2017

Kiyomi Ito

1 reference

14 October 2017

Koji Chiba

1 reference

14 October 2017

Masato Horikawa

1 reference

14 October 2017

Michi Ishigami

1 reference

14 October 2017

Naomi Mizuno

1 reference

14 October 2017

Jun Aoki

1 reference

14 October 2017

Yasumasa Gotoh

1 reference

14 October 2017

Takafumi Iwatsubo

1 reference

14 October 2017

Shin-ichi Kanamitsu

1 reference

14 October 2017

Motohiro Kato

1 reference

14 October 2017

Iichiro Kawahara

1 reference

14 October 2017

Kayoko Niinuma

1 reference

14 October 2017

Akiko Nishino

1 reference

14 October 2017

Norihito Sato

1 reference

14 October 2017

Yuko Tsukamoto

1 reference

14 October 2017

Kaoru Ueda

1 reference

14 October 2017

Tomoo Itoh

1 reference

14 October 2017

Yuichi Sugiyama

1 reference

14 October 2017

1 January 2002

1 reference

14 October 2017

1 reference

14 October 2017

1 reference

14 October 2017

1 reference

14 October 2017

E25

1 reference

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Protease inhibitors for the treatment of human immunodeficiency virus infection

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Clinical Pharmacokinetics of Nefazodone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Effect of fluconazole dose on the extent of fluconazole-triazolam interaction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Stereoselective interaction between piroxicam and acenocoumarol

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

The safety profile of nefazodone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Newer antidepressants and the cytochrome P450 system

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Dangerous interaction between amiodarone and quinidine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Ciprofloxacin increases serum levels of theophylline

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Diazepam and methadone blood levels following concurrent administration of diazepam and methadone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4-Hydroxylase) by Flecainide In Vitro and In Vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Effect of venlafaxine on the pharmacokinetics of alprazolam.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751314

High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients

25 November 2018

1 reference

12 December 2020

Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine

1 reference

12 December 2020

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

12 December 2020

Mexiletine and caffeine elimination

1 reference

12 December 2020

Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients

1 reference

12 December 2020

Interaction between propranolol and propafenone in healthy volunteers

1 reference

12 December 2020

Cyclosporine--high-dose steroid interaction in renal transplant recipients: assessment by HPLC

1 reference

12 December 2020

Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients

1 reference

12 December 2020

Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans

1 reference

12 December 2020

Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

1 reference

12 December 2020

Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects

1 reference

12 December 2020

Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1 reference

12 December 2020

Pharmacokinetic interactions of nifedipine and quinidine

1 reference

12 December 2020

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole

1 reference

12 December 2020

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

1 reference

12 December 2020

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

12 December 2020

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients

1 reference

12 December 2020

Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver

1 reference

12 December 2020

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone

1 reference

12 December 2020

Effects of cimetidine and ranitidine on hepatic drug metabolism

1 reference

12 December 2020

Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects

1 reference

12 December 2020

Identifiers

DOI

10.1208/PS040425

1 reference

release_54diz32d7bc2hnlylax5qc4hf4

14 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/54diz32d7bc2hnlylax5qc4hf4

24 November 2022

mapped directly with Wikidata item

1 reference

14 October 2017

PubMed publication ID

12645997

1 reference